Literature DB >> 33385528

Correlation of Patient Activation Measure Level with Patient Characteristics and Type of Vascular Disease.

Misty D Humphries1, Pierce Welch2, Jason Hasegawa2, Matthew W Mell2.   

Abstract

BACKGROUND: Patient activation or level of engagement in one's medical care is linked to hospital readmissions and worse outcomes in a number of diseases. Patients with higher levels of activation are typically guiding their care rather than acting as passive observers of care. This study aims to determine if either patient demographics or type of vascular disease can predict patient activation.
METHODS: All patients presenting over a 4-month period to an outpatient vascular clinic were asked to complete the Patient Activation Measure (PAM) survey. In total, 257 completed surveys were collected. Survey responses were scored on a Likert scale with anchors. Responses are tallied with a score of 1-100 and converted to summary levels 1-4 in accordance with the previously validated scoring system. Level 1 patients are considered disengaged and overwhelmed. Patients in level 2 are becoming aware of their health care, but still struggle. Level 3 patients are taking action, while level 4 represents patients who are maintaining healthy behaviors and pushing further. Chi-squared test and multivariable regression were then performed to determine if patient characteristics or type of disease correlated with activation levels.
RESULTS: In total, 257 patients completed the survey. The mean participant age was 67 years (±15). Sixteen percent of patients lived alone, 58% were married, and in 39% mean household income was <$50,000. Overall, 21 patients (8.2%) were classified as level 1, 65 (25%) level 2, 94 (37%) level 3, and 77 (30%) level 4. The group comprised 32% peripheral artery disease (PAD), 20% carotid, 18% aortic/aneurysm, 14% venous, and 16% were various other vascular diseases. Over each disease group there was a wide range of activation, but no significant difference between the type of vascular disease and activation level. Chronic limb-threatening ischemia (CLTI) patients comprised 35% (n = 29) of the PAD group, and 66% of these patients reported an activation level of 3 (n = 10) or 4 (n = 9). There was no difference in the levels of activation reported by the CLTI patients compared to the general PAD cohort (P = 0.99). Multivariable analysis demonstrated that age, level of education, household income, and type of vascular disease correlated with PAM score, but there was no correlation between length of symptoms, race, or gender.
CONCLUSIONS: Patient activation is unpredictable using patient characteristics or type of vascular disease, and CLTI patients report high activation levels. Quality databases that collect only patient demographics may not fully capture patient predictors of poor outcomes. Use of the PAM survey should be further explored in vascular patients to correlate activation level with vascular-specific outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33385528      PMCID: PMC8882319          DOI: 10.1016/j.avsg.2020.11.019

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  19 in total

1.  How good is the quality of health care in the United States? 1998.

Authors:  Mark A Schuster; Elizabeth A McGlynn; Robert H Brook
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

2.  Analysis of gender-related differences in lower extremity peripheral arterial disease.

Authors:  Natalia Egorova; Ageliki G Vouyouka; Jacquelyn Quin; Stephanie Guillerme; Alan Moskowitz; Michael Marin; Peter L Faries
Journal:  J Vasc Surg       Date:  2010-02       Impact factor: 4.268

3.  Racial Disparities in Endovascular Aortic Aneurysm Repair.

Authors:  Adam Tanious; Nirmani Karunathilake; Joel Toro; Afif Abu-Hanna; Laura T Boitano; Timothy Fawcett; Brian Graves; Peter Nelson
Journal:  Ann Vasc Surg       Date:  2018-11-23       Impact factor: 1.466

4.  Patient-physician role relationships and patient activation among individuals with chronic illness.

Authors:  Jeffrey A Alexander; Larry R Hearld; Jessica N Mittler; Jillian Harvey
Journal:  Health Serv Res       Date:  2011-11-18       Impact factor: 3.402

5.  Racial and ethnic differences in patterns of treatment for acute peripheral arterial disease in the United States, 1998-2006.

Authors:  Vincent L Rowe; Fred A Weaver; John S Lane; David A Etzioni
Journal:  J Vasc Surg       Date:  2010-01-15       Impact factor: 4.268

6.  Improving Population Health Management Strategies: Identifying Patients Who Are More Likely to Be Users of Avoidable Costly Care and Those More Likely to Develop a New Chronic Disease.

Authors:  Judith H Hibbard; Jessica Greene; Rebecca M Sacks; Valerie Overton; Carmen Parrotta
Journal:  Health Serv Res       Date:  2016-08-22       Impact factor: 3.402

7.  Racial and ethnic disparities in outcomes and appropriateness of carotid endarterectomy: impact of patient and provider factors.

Authors:  Ethan A Halm; Stanley Tuhrim; Jason J Wang; Mary Rojas; Caron Rockman; Thomas S Riles; Mark R Chassin
Journal:  Stroke       Date:  2009-05-21       Impact factor: 7.914

8.  Patient Activation as a Pathway to Shared Decision-making for Adults with Diabetes or Cardiovascular Disease.

Authors:  Bing Ying Poon; Stephen M Shortell; Hector P Rodriguez
Journal:  J Gen Intern Med       Date:  2019-10-23       Impact factor: 5.128

9.  The role of primary care providers in patient activation and engagement in self-management: a cross-sectional analysis.

Authors:  Carmen Alvarez; Jessica Greene; Judith Hibbard; Valerie Overton
Journal:  BMC Health Serv Res       Date:  2016-03-11       Impact factor: 2.655

10.  Patient activation in older people with long-term conditions and multimorbidity: correlates and change in a cohort study in the United Kingdom.

Authors:  Amy Blakemore; Mark Hann; Kelly Howells; Maria Panagioti; Mark Sidaway; David Reeves; Peter Bower
Journal:  BMC Health Serv Res       Date:  2016-10-18       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.